Leadership Shift: CytoDyn Names Cyrus Arman, Ph.D., MBA, as New President to Lead Leronlimab Development

Strategic Appointment Signals New Direction for Biotech Company

CytoDyn Inc. (OTCQB: CYDY), the clinical-stage biotechnology firm advancing leronlimab as a potential therapeutic across multiple disease areas, has named Cyrus Arman, Ph.D., MBA, to the role of President, effective July 9, 2022. The move marks a significant leadership transition as the company looks to accelerate its development and commercialization strategy.

Arman will take charge of setting and executing the Company’s strategic direction moving forward. Board leadership has indicated he is on track for promotion to Chief Executive Officer with concurrent Board appointment within the next six months. Meanwhile, Antonio Migliarese, who stepped in as interim President back in late January while maintaining CFO duties, will transition back to focus exclusively on financial operations.

Who Is Cyrus Arman?

The newly appointed President brings substantial pedigree to the role, with 15+ years navigating the biotechnology and corporate strategy landscape. Most recently, Arman held the Chief Business Officer position at Nimble Therapeutics, where he led deal structuring, partnership negotiations, and licensing initiatives alongside broader corporate strategy work.

His prior tenure as Vice President of Corporate Development and Strategy at NEUVOGEN, Inc., an early-stage immuno-oncology startup, exposed him to the challenges of scaling emerging biotech ventures. He also spent time as a director within Amgen’s Corporate Strategy division, overseeing the firm’s Global Competitive Intelligence and Strategy operations.

Earlier in his career, Arman worked as a management consultant, advising major pharmaceutical and diagnostics companies on multi-billion-dollar business development decisions and partnership structuring. He has also served as an adjunct professor at the University of Southern California and contributed to peer-reviewed scientific publications.

Educational Foundation

Arman holds an MBA from UCLA Anderson School of Management, a Ph.D. in Neuroscience, and an MS in Biomedical Engineering, both from USC Keck School of Medicine. His undergraduate degree in Biopsychology comes from the University of California San Diego—a blend of scientific rigor and business acumen that the Board clearly sought.

Board’s Rationale

Tanya Urbach, Board Chair, highlighted that Arman’s “methodical, analytical and inspired approach” stood out during the recruitment process. She emphasized his combination of capital markets expertise, corporate governance experience, and scientific knowledge as the ideal mix to “competitively position the Company” and unlock shareholder value by identifying the most promising therapeutic pathways for leronlimab.

What’s Next

According to Arman’s statement, the priority is “uniting our teams in the pursuit of CytoDyn’s success through a renewed focus on the entrepreneurial spirit.” He spotlighted leronlimab as “a unique molecule with the potential to help many individuals” facing unmet medical needs, signaling the Company’s intention to refine clinical development timelines and cultivate strategic partnerships that accelerate funding and advancement of its pipeline.

About CytoDyn

CytoDyn is a clinical-stage biotech company developing leronlimab, a humanized IgG4 monoclonal antibody engineered to bind to CCR5 (C-C chemokine receptor type 5), a cell-surface protein implicated in various disease pathways. The company is exploring leronlimab across infectious disease, cancer, and autoimmune indications, positioning it as a potentially multi-indication asset in the development pipeline.